The Pharma Challenge With Scope 3 Emissions – Collaborative Ways to Reduce Our CO2 Footprint

Big Pharma reports that up to over 90% of their CO2 emissions are scope 3. This is not only a huge burden but also the most difficult part to influence for pharmaceutical industry. However, there are ways to manage and collaborate in the industry. Christophe Marie from Aptar Group will highlight how Aptar implemented specific targets with partners and suppliers to tackle the scope 3 challenge, coming from a consumer market perspective, extrapolating into the pharmaceutical business. Also, when talking about products we are increasingly facing requests to minimize our CO2 footprint in Pharma. A great example for collaborative approaches helping to de-risk and accelerate our clients’ low GWP pressurized Metered Dose Inhaler (pMDI) programs will be illustrated by Chris Baron, based on the transition of the current pMDIs to alternative low GWP propellant technologies. Join Christophe Marie and Chris Baron at CPHI to learn how Aptar Pharma supports more sustainable product